JIN Historical Income Statement

ZJYL Stock

0.92 0.01 1.10%

Historical analysis of JIN MEDICAL income statement accounts such as Depreciation And Amortization of 254.9 K, Interest Expense of 8.1 K, Selling General Administrative of 2 M or Selling And Marketing Expenses of 464.3 K can show how well JIN MEDICAL INTERNATIONAL performed in making a profits. Evaluating JIN MEDICAL income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of JIN MEDICAL's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining JIN MEDICAL INTERNATIONAL latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether JIN MEDICAL INTERNATIONAL is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in JIN MEDICAL INTERNATIONAL. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

About JIN Income Statement Analysis

JIN MEDICAL INTERNATIONAL Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to JIN MEDICAL shareholders. The income statement also shows JIN investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

JIN MEDICAL Income Statement Chart

At this time, JIN MEDICAL's Depreciation And Amortization is quite stable compared to the past year. Selling General Administrative is expected to rise to about 2 M this year, although the value of Selling And Marketing Expenses will most likely fall to about 464.3 K.

Selling General Administrative Selling And Marketing Expenses Gross Profit

Gross Profit

Gross profit is a required income statement account that reflects total revenue of JIN MEDICAL INTERNATIONAL minus its cost of goods sold. It is profit before JIN MEDICAL operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most accounts from JIN MEDICAL's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into JIN MEDICAL INTERNATIONAL current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in JIN MEDICAL INTERNATIONAL. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

	2023	2024 (projected)
Interest Expense	8.5K	8.1K
Depreciation And Amortization	203.3K	254.9K

Interest Expense Depreciation And Amortization

JIN MEDICAL income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Tax Provision	Net Interest Income	Net Income From Continuing Ops	Reconciled Depreciation	Interest Income
Depreciation And Amortization		0.2	-0.82	-0.78	-0.37	-0.06	-0.63	0.54	0.63	-0.58	0.66	-0.49	-0.64	0.51	-0.49	0.56	0.27	-0.88	-0.77	-0.85	0.99	0.64
Interest Expense	0.2		-0.44	-0.37	-0.84	-0.56	-0.73	-0.1	-0.13	-0.31	-0.12	-0.81	-0.23	-0.23	-0.19	-0.23	-0.19	-0.25	-0.41	-0.41	0.25	0.24
Selling General Administrative	-0.82	-0.44		0.65	0.28	-0.07	0.58	-0.53	-0.57	0.64	-0.59	0.44	0.91	-0.44	0.58	-0.46	-0.33	0.68	0.84	0.78	-0.79	-0.43
Selling And Marketing Expenses	-0.78	-0.37	0.65		0.49	-0.11	0.88	-0.7	-0.74	0.78	-0.76	0.78	0.38	-0.65	0.72	-0.69	-0.47	0.83	0.78	0.92	-0.71	-0.59
Total Revenue	-0.37	-0.84	0.28	0.49		0.77	0.78	0.18	0.15	0.18	0.13	0.9	-0.01	0.25	0.04	0.21	0.35	0.47	0.31	0.44	-0.45	-0.44
Gross Profit	-0.06	-0.56	-0.07	-0.11	0.77		0.22	0.71	0.67	-0.41	0.64	0.41	-0.19	0.73	-0.54	0.7	0.8	0.14	-0.21	-0.11	-0.21	-0.13
Other Operating Expenses	-0.63	-0.73	0.58	0.88	0.78	0.22		-0.46	-0.47	0.74	-0.48	0.96	0.24	-0.37	0.64	-0.39	-0.28	0.64	0.76	0.86	-0.6	-0.59
Operating Income	0.54	-0.1	-0.53	-0.7	0.18	0.71	-0.46		0.99	-0.89	0.98	-0.23	-0.36	0.98	-0.93	0.97	0.95	-0.35	-0.8	-0.76	0.39	0.48
Ebit	0.63	-0.13	-0.57	-0.74	0.15	0.67	-0.47	0.99		-0.86	1.0	-0.24	-0.41	0.98	-0.89	0.99	0.9	-0.46	-0.8	-0.78	0.49	0.52
Research Development	-0.58	-0.31	0.64	0.78	0.18	-0.41	0.74	-0.89	-0.86		-0.86	0.54	0.37	-0.81	0.99	-0.79	-0.83	0.4	0.93	0.9	-0.46	-0.5
Ebitda	0.66	-0.12	-0.59	-0.76	0.13	0.64	-0.48	0.98	1.0	-0.86		-0.26	-0.43	0.98	-0.88	0.98	0.89	-0.49	-0.81	-0.8	0.53	0.54
Cost Of Revenue	-0.49	-0.81	0.44	0.78	0.9	0.41	0.96	-0.23	-0.24	0.54	-0.26		0.11	-0.15	0.43	-0.18	-0.06	0.58	0.58	0.7	-0.49	-0.54
Total Operating Expenses	-0.64	-0.23	0.91	0.38	-0.01	-0.19	0.24	-0.36	-0.41	0.37	-0.43	0.11		-0.29	0.35	-0.31	-0.19	0.55	0.57	0.49	-0.62	-0.12
Income Before Tax	0.51	-0.23	-0.44	-0.65	0.25	0.73	-0.37	0.98	0.98	-0.81	0.98	-0.15	-0.29		-0.85	1.0	0.94	-0.33	-0.72	-0.68	0.37	0.51
Total Other Income Expense Net	-0.49	-0.19	0.58	0.72	0.04	-0.54	0.64	-0.93	-0.89	0.99	-0.88	0.43	0.35	-0.85		-0.82	-0.89	0.33	0.87	0.83	-0.36	-0.4
Net Income	0.56	-0.23	-0.46	-0.69	0.21	0.7	-0.39	0.97	0.99	-0.79	0.98	-0.18	-0.31	1.0	-0.82		0.9	-0.39	-0.71	-0.7	0.43	0.55
Income Tax Expense	0.27	-0.19	-0.33	-0.47	0.35	0.8	-0.28	0.95	0.9	-0.83	0.89	-0.06	-0.19	0.94	-0.89	0.9		-0.04	-0.67	-0.57	0.12	0.35
Tax Provision	-0.88	-0.25	0.68	0.83	0.47	0.14	0.64	-0.35	-0.46	0.4	-0.49	0.58	0.55	-0.33	0.33	-0.39	-0.04		0.53	0.73	-0.88	-0.4
Net Interest Income	-0.77	-0.41	0.84	0.78	0.31	-0.21	0.76	-0.8	-0.8	0.93	-0.81	0.58	0.57	-0.72	0.87	-0.71	-0.67	0.53		0.94	-0.69	-0.65
Net Income From Continuing Ops	-0.85	-0.41	0.78	0.92	0.44	-0.11	0.86	-0.76	-0.78	0.9	-0.8	0.7	0.49	-0.68	0.83	-0.7	-0.57	0.73	0.94		-0.78	-0.63
Reconciled Depreciation	0.99	0.25	-0.79	-0.71	-0.45	-0.21	-0.6	0.39	0.49	-0.46	0.53	-0.49	-0.62	0.37	-0.36	0.43	0.12	-0.88	-0.69	-0.78		0.63
Interest Income	0.64	0.24	-0.43	-0.59	-0.44	-0.13	-0.59	0.48	0.52	-0.5	0.54	-0.54	-0.12	0.51	-0.4	0.55	0.35	-0.4	-0.65	-0.63	0.63

Click cells to compare fundamentals

JIN MEDICAL Account Relationship Matchups

JIN MEDICAL income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	324.9K	341.2K	357.3K	225.9K	203.3K	254.9K
Selling General Administrative	1.5M	1.7M	1.8M	2.4M	1.9M	2.0M
Selling And Marketing Expenses	385.1K	489.0K	402.0K	453.3K	521.3K	464.3K
Total Revenue	16.2M	20.8M	19.2M	19.8M	22.8M	21.3M
Gross Profit	5.5M	6.4M	6.2M	6.8M	7.8M	7.2M
Other Operating Expenses	13.8M	18.1M	17.1M	17.0M	19.5M	18.0M
Operating Income	2.4M	2.6M	2.1M	2.9M	2.6M	2.3M
Ebit	2.5M	2.9M	2.7M	2.9M	2.6M	2.5M
Research Development	1.3M	1.6M	1.9M	1.5M	1.8M	1.6M
Ebitda	2.8M	3.2M	3.1M	3.1M	2.8M	2.7M
Cost Of Revenue	10.7M	14.4M	13.0M	13.0M	15.0M	14.1M
Total Operating Expenses	3.1M	3.7M	4.1M	17.0M	3.9M	6.4M
Income Before Tax	2.4M	2.9M	2.7M	3.2M	2.9M	2.5M
Total Other Income Expense Net	(1.5K)	248.8K	612.1K	172.0K	354.7K	203.4K
Net Income	2.2M	2.6M	2.7M	2.9M	2.6M	2.3M
Income Tax Expense	147.2K	248.6K	36.1K	343.7K	309.3K	200.8K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether JIN MEDICAL INTERNATIONAL is a strong investment it is important to analyze JIN MEDICAL's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact JIN MEDICAL's future performance. For an informed investment choice regarding JIN Stock, refer to the following important reports:

How To Invest In JIN

Details

Is JIN Stock a good investment?

Details

What is JIN MEDICAL's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of JIN MEDICAL. If investors know JIN will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about JIN MEDICAL listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.12)

Earnings Share

0.02

Revenue Per Share

0.129

Quarterly Revenue Growth

0.03

Return On Assets

0.0403

The market value of JIN MEDICAL INTERNATIONAL is measured differently than its book value, which is the value of JIN that is recorded on the company's balance sheet. Investors also form their own opinion of JIN MEDICAL's value that differs from its market value or its book value, called intrinsic value, which is JIN MEDICAL's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because JIN MEDICAL's market value can be influenced by many factors that don't directly affect JIN MEDICAL's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between JIN MEDICAL's value and its price as these two are different measures arrived at by different means. Investors typically determine if JIN MEDICAL is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, JIN MEDICAL's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

JIN Historical Income Statement

About JIN Income Statement Analysis

JIN MEDICAL Income Statement Chart

Gross Profit

JIN MEDICAL income statement Correlations

JIN MEDICAL Account Relationship Matchups

High Positive Relationship

High Negative Relationship

JIN MEDICAL income statement Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Reconciled Depreciation	+ 0.99	Depreciation And Amortization
Ebit	+ 0.99	Operating Income
Net Income	+ 0.99	Ebit
Total Other Income Expense Net	+ 0.99	Research Development

Total Other Income Expense Net	- 0.93	Operating Income
Income Tax Expense	- 0.89	Total Other Income Expense Net
Total Other Income Expense Net	- 0.89	Ebit
Research Development	- 0.89	Operating Income
Reconciled Depreciation	- 0.88	Tax Provision
Total Other Income Expense Net	- 0.88	Ebitda